Research using human brain organoids onboard the International Space Station helped lead to a clinical trial of a potential ...

-- First and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S. 1 SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc.

Rett syndrome is a rare neurodevelopment disorder that leads to developmental regression, usually after a period of normal growth, and causes impairments in communication, motor skills, and speech. It ...

Though many studies approach the developmental disorder Rett syndrome as a single condition arising from general loss of function in the gene MECP2, a new study by neuroscientists at The Picower ...

David Lieberman, MD, PhD, reviews the potential role and the goals of gene therapy in the treatment of Rett syndrome. The goals of therapy, as I see it for Rett syndrome, should be treating the ...

The Food and Drug Administration on Friday approved the first treatment for Rett syndrome, a genetic disease mostly affecting girls that causes severe neurologic impairments, robbing them of the ...

Gene therapy may offer hope for people with a rare childhood disease called Rett syndrome. Around one in 10,000 girls are born each year with Rett syndrome, a rare genetic condition that impacts brain ...

An expert highlights unmet needs in the treatment of Rett syndrome. Paige Nues: The biggest unmet need for Rett syndrome is that there is no intervention or cure for this disorder. Onset is between 6 ...

New discoveries about the severe developmental disorder known as Rett syndrome could open the door to better treatments for the devastating, life-shortening condition. Scientists investigating the ...

--DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare, neurodevelopmental disorder SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) ...

Modulating alternative splicing of the MECP2 gene has been identified as a potential therapeutic strategy for Rett syndrome. A team of researchers at Texas Children’s Duncan Neurological Research ...

Acadia Pharmaceuticals announced last Friday that the FDA approved DAYBUE (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. DAYBUE is the ...